EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice

Shubham Sahni, Lata Rani, Ritu Gupta, Ajay Gogia

Frontiers in Oncology · 15.07.2026 · 16

DOI: 10.3389/fonc.2026.1853089 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 15.07.2026. Verfasst von Shubham Sahni und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS), New Delhi, Ind…. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Management of Chronic lymphocytic leukemia (CLL) has undergone a paradigm shift, moving from chemoimmunotherapy (CIT) to precision, biology-driven treatment with targeted agents. While these advances have rapidly reshaped practice in high-resource nations, their integration into routine care in India is limited by differences in epidemiology, healthcare infrastructure, drug access, and economic constraints. CLL remains relatively uncommon in India, with patients presenting at a younger age and historically at more advanced stages of disease. Nevertheless, there is a temporal shift towards earlier diagnosis with the wider use of hematological testing. Risk stratification has also evolved from clinical staging to molecular profiling incorporating TP53 mutation testing, IGHV mutation status, and cytogenetic abnormalities. However, access to molecular profiling remains limited across India, directly influencing therapeutic decision-making. Bruton tyrosine kinase inhibitors (BTKi) and BCL-2 inhibitors have demonstrated superior efficacy and tolerability compared to CIT across biological subgroups and are endorsed by international guidelines. In India, treatment selection continues to balance biological risk with access and affordability. The introduction of generic ibrutinib has been important, especially for TP53 mutated CLL, while uptake of venetoclax-based fixed-duration regimens has been limited by cost and monitoring requirements. CIT retains a limited role in selected young, IGHV-mutated patients with durable responses. This review examines contemporary CLL management through an Indian lens, emphasizing how global advances intersect with real-world constraints and influence local practice. Improving access to molecular diagnostics and targeted agents along with health-policy reforms is essential to narrow the outcome gap between Indian and Western patients with CLL.

Schlagwörter

Stichwörter der Autor:innen

BTK inhibitorsIndiachemoimmunotherapychronic lymphocytic leukemiacost-effectivenessminimal residual diseasevenetoclax

Autor:innen und Institutionen

  • Department of Medical Oncology, Dr. B. R. A. Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS), New Delhi, India.
  • Genomics Lab, Centralized Core Research Facility (CCRF), All India Institute of Medical Sciences, New Delhi, India.
  • Laboratory Oncology Unit, Dr. B. R. A. Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Zitieren

APA

Sahni, S., Rani, L., Gupta, R., & Gogia, A. (2026). Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1853089

Vancouver

Sahni S, Rani L, Gupta R, Gogia A. Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1853089

BibTeX
@article{Sahni2026,
  author = {Sahni, Shubham and Rani, Lata and Gupta, Ritu and Gogia, Ajay},
  title = {Chronic lymphocytic leukemia management in India: balancing evidence, access, and affordability in clinical practice},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1853089}
}
Kostenlos starten →